Medical and Science
Loss of smell ‘first sign’ of COVID-19, experts say
Medical News: Medical experts in countries hit by COVID-19 are reporting the first tell-tale signs of the virus may be in an unexpected loss in smell.
Ear, nose and throat (ENT) surgeons say loss of smell – as the virus causes swelling in the olfactory mucosa more than other viruses – could be used as a key clinical indicator in otherwise symptom-free carriers of COVID-19.
“It is these ‘silent carriers’ who may remain undetected by current screening procedures, which may explain why the disease has progressed so rapidly in so many countries around the world,” says South Australian specialist Flinders University Professor Simon Carney, from the Southern ENT and Adelaide Sinus Centre.
“While further research is required, loss of smell, or anosmia, has been reported in as many as 1 in 3 patients in South Korea and, in Germany, this figure was as high as 2 in patients,” says Professor of Otolaryngology (head and neck surgery) at Flinders University.
Register FREE and join 20,000+ industry professionals who receive the latest industry news, innovations and insights from Health Industry Hub; the ONLY one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals.
“An ENT professor in London has reported seeing a dramatic increase in patients with anosmia as their only symptom of COVID-19 infection.”
As Australia struggles to contain the spread of COVID-19, identification of these carriers could help to slow the spread of infection.
“In the UK, ENT surgeons are pushing to have anosmia highlighted as an important symptom that may signify a patient may be an asymptomatic carrier,” says Professor Carney, immediate past president of the Australia and New Zealand Rhinologic Society.
“Australia is in a position to take advantage of these findings overseas to try and ‘flatten the curve’ while we still can.”
Doctors and COVID-19 detection centres could use this subtle sign and unexplained sudden anosmia in the testing criteria, he says.
Patients should also consider calling their GP with this early symptom as a precursor for possible treatment.
HCP engagement during COVID-19. Health Industry Hub combines expertise in target audience insights, delivering digital health content and measuring engagement with 20+ years industry experience. Created by industry for industry.
News & Trends - Pharmaceuticals
March PBAC agenda unveiled amid tensions over ‘unprecedented’ volume of submissions
The Department of Health has released the agenda for the March 2025 Pharmaceutical Benefits Advisory Committee (PBAC) meeting, unveiling plans […]
MoreNews & Trends - MedTech & Diagnostics
J&J MedTech exits DePuy Synthes spine portfolio
Johnson & Johnson MedTech will officially exit the DePuy Synthes Spine portfolio in Australia tomorrow, November 30, as part of […]
MoreNews & Trends - Pharmaceuticals
Home-grown hypertension polypill heads to regulatory approval
Australian-supported research has revealed remarkable Phase III clinical trial results for an innovative triple drug combination in the treatment of […]
MoreNews & Trends - Pharmaceuticals
Will Australia become first country to eliminate HIV transmission by 2030?
In the lead-up to World AIDS Day on December 1, the Albanese Government has unveiled the 9th National HIV Strategy, […]
More